About 30 results found for searched term "Cholic acid" (0.021 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M25448 | Dehydrolithocholic acid | ROR |
| 3-Oxo-5β-cholanoic acid | ||
| Dehydrolithocholic acid is a bile acid metabolite, which inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (Kd=1.13 μM). | ||
| M11303 | Glycodeoxycholic Acid | Metabolite/Endogenous Metabolite |
| Glycodeoxycholic Acid is an endogenous metabolite. | ||
| M11304 | Glycolithocholic acid | Metabolite/Endogenous Metabolite |
| Glycolithocholic acid, an endogenous metabolite, is a glycine conjugated secondary bile acid. Glycolithocholic acid can be used to study ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH0) and primary sclerosing cholangitis (PSC). | ||
| M2507 | Chenodeoxycholic acid | Farnesoid X Receptor |
| CDCA; Chenodiol | ||
| Chenodeoxycholic acid is an epimer of ursodeoxycholic acid, which inhibits the production of cholesterol in the liver and absorption in the intestines. | ||
| M2816 | Lithocholic acid | Ferroptosis |
| 3α-Hydroxy-5β-cholanic acid | ||
| Lithocholic acid is a bile acid that acts as a detergent to solubilize fats for absorption, can also activate the vitamin D receptor. | ||
| M3775 | Obeticholic Acid (INT-747) | Farnesoid X Receptor |
| 6-ECDCA; UNII-0462Z4S4OZ; OCA; 6-Ethylchenodeoxycholic acid | ||
| Obeticholic Acid (INT-747) is a potent, orally active, selective farnesoid X receptor (FXR) agonist with an EC50 of 99 nM.May be used in studies related to non-alcoholic steatohepatitis (NASH). | ||
| M5158 | Tauroursodeoxycholic acid (Ursodoxicoltaurine) | ERK |
| TUDCA; Ursodoxicoltaurine; Ursodeoxycholyltaurine; Tauroursodeoxycholate; UR 906; Taurursodiol | ||
| Tauroursodeoxycholic acid (Ursodoxicoltaurine) is an endoplasmic reticulum stress inhibitor. It can significantly reduce the expression of apoptotic molecules such as caspase-3 and caspase-12. Tauroursodeoxycholate also suppresses ERK. It is a taurine conjugate of usodeoxycholic acid. | ||
| M11152 | Deoxycholic acid sodium salt | GPCR19/TGR5 |
| Sodium deoxycholate | ||
| Deoxycholic acid sodium salt activates the G protein-coupled bile acid receptor TGR5. | ||
| M5340 | Tauroursodeoxycholate Sodium | ERK |
| TUDCA; Sodium tauroursodeoxycholate; Tauroursodeoxycholic acid sodium salt | ||
| Sodium Tauroursodeoxycholate (TUDC) is a water soluble bile salt, used for the treatment of gallstones and liver cirrhosis. | ||
| M5560 | Dehydrocholic acid | Others |
| Decholin, Dehystolin, Felacrinos, Sanocholen | ||
| Dehydrocholic acid is a semisynthetic bile acid made from cholic acid. It is used as a cholagogue, hydrocholeretic, diuretic, and as a diagnostic aid. | ||
| M5563 | Deoxycholic acid | Others |
| Deoxycholate, Desoxycholic acid, Cholerebic, Cholorebic | ||
| Deoxycholic acid is a cytolytic agent. The physiologic effect of deoxycholic acid is by means of decreased cell membrane integrity. | ||
| M11301 | Glycohyodeoxycholic acid | Metabolite/Endogenous Metabolite |
| Glycohyodeoxycholic acid is the main metabolite of Hyodeoxycholic acid in human body, which can prevent the formation of gallstones. | ||
| M5990 | Taurocholic Acid sodium hydrate | Metabolite/Endogenous Metabolite |
| Sodium taurocholate hydrate | ||
| Taurocholic acid sodium hydrate is a deliquescent yellowish crystalline bile acid involved in the emulsification of fats. In medical use, it is administered as a cholagogue. | ||
| M6047 | Ursodiol | Animal Modeling |
| UDCA；Ursodeoxycholic acid; UDCS；Ursodeoxycholate; Ursodiol | ||
| Ursodiol reduces cholesterol absorption and is used to dissolve (cholesterol) gallstones with an IC50 of 0.22 μM. Ursodeoxycholic acid (UDCA), which reduces FXR and closes the ACE2 channel. It can be used to construct animal models of cholelithiasis. | ||
| M9192 | Cholic acid | Metabolite/Endogenous Metabolite |
| Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. | ||
| M9212 | Aramchol | Stearoyl-CoA Desaturase |
| Arachidyl amido cholanoic acid; C20-FABAC; Icomidocholic acid | ||
| Aramchol is a novel fatty acid bile acid coupling agent with oral activity and an inhibitor of SCD1, which acts by inhibiting SCD1 expression in hepatocytes and hepatic astrocytes, and can be used in studies related to non-alcoholic steatohepatitis (NASH). | ||
| M9408 | Glycochenodeoxycholic acid | Metabolite/Endogenous Metabolite |
| Chenodeoxycholylglycine | ||
| Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a bile acid formed in the liver from chenodeoxycholate and glycine. | ||
| M9409 | Glycoursodeoxycholic acid | Metabolite/Endogenous Metabolite |
| Ursodeoxycholylglycine | ||
| Glycoursodeoxycholic acid, a acyl glycine and a bile acid-glycine conjugate, is a metabolite of ursodeoxycholic acid. | ||
| M9952 | Glycocholic acid | Metabolite/Endogenous Metabolite |
| Glycocholic acid is a bile acid which has anticancer activity. | ||
| M9953 | Taurocholic acid | Metabolite/Endogenous Metabolite |
| N-Choloyltaurine | ||
| Taurocholic acid (N-Choloyltaurine) is a bile acid, which can be used in the emulsification of fats. | ||
| M10251 | Gly-β-MCA | Farnesoid X Receptor |
| Glycine-β-muricholic Acid | ||
| Gly-β-MCA is a potent, stable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor. | ||
| M10946 | Glyco-Obeticholic acid | Others |
| Glyco-obeticholic acid is an active metabolite of taurine. Obeticholic Acid is an oral bioavailable fancy-like X receptor (FXR) agonist. | ||
| M11050 | Tauroursodeoxycholate dihydrate | ERK |
| Tauroursodeoxycholic acid dihydrate | ||
| Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an endoplasmic reticulum stress inhibitor. Tauroursodeoxycholate significantly reduces the expression of apoptotic molecules such as caspase-3 and caspase-12. Tauroursodeoxycholate also suppresses ERK. | ||
| M11178 | Taurochenodeoxycholic acid | Apoptosis |
| Taurochenodeoxycholate, TCDCA, 12-Deoxycholyltaurine, Chenodeoxycholyltaurine, Chenyltaurine | ||
| Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animal bile acids. Taurochenodeoxycholic acid induces apoptosis (apoptosis) and has a pronounced anti-inflammatory and immunomodulatory effect. | ||
| M11414 | Hyodeoxycholic acid | Metabolite/Endogenous Metabolite |
| HDCA; NSC 60672 | ||
| Hyodeoxycholic acid is a secondary bile acid formed by intestinal flora in the small intestine and is an agonist of TGR5 (GPCR19). In CHO cells, the EC50 value is 31.6 µM. | ||
| M11507 | Taurolithocholic acid sodium salt | Calcium Channel |
| Taurolithocholic acid sodium salt is an effective bile suppressor and Ca2+ agonist. | ||
| M13346 | Taurodeoxycholate sodium salt | Metabolite/Endogenous Metabolite |
| Sodium Taurodeoxycholate; Taurodeoxycholic acid sodium salt | ||
| Taurodeoxycholate sodium salt is a bile salt formed in the liver by conjugation of deoxycholate with taurine, usually as the sodium salt. It is used as a cholagogue and choleretic, also industrially as a fat emulsifier. | ||
| M13350 | 7-Ketolithocholic acid | Metabolite/Endogenous Metabolite |
| 3α-Hydroxy-7-oxo-5β-cholanic acid | ||
| 7-ketolithocholic acid (3α -hydroxy-7-oxo-5 β-cholanic acid) is a derivative of cholcholic acid, which can be absorbed to inhibit endogenous bile acid production and bile cholesterol secretion. Cholic acid is also used as a cholic acid derivative of TGR5 regulators. | ||
| M15050 | Hyocholic Acid | Others |
| γ-Muricholic Acid | ||
| Hyocholic acid is a primary bile acid in pigs and other mammals. | ||
| M13985 | Ursodeoxycholic acid sodium | GPCR19/TGR5 |
| Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium | ||
| Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
